Knockdown of TOP2A reverses cisplatin resistance in ovarian cancer by inhibiting EMT via ferroptosis mediated by the TP53/GPX4/SLC7A11 axis
TOP2A represents a potential prognostic biomarker and therapeutic target for cisplatin resistance in ovarian cancer (OC), as it regulates ferroptosis and EMT via the TP53/GPX4/SLC7A11 axis, which is mediated by its direct interaction with TP53. This thus provides a novel direction for treating cisplatin-resistant OC.
Authors
- Yang‐Yu Liu (ORCID: https://orcid.org/0000-0003-2728-4907)
- Shouhong Gao (ORCID: https://orcid.org/0000-0002-8322-4637)
- Zhihai Qin (ORCID: https://orcid.org/0000-0001-9793-7964)
- Yuping Suo
- Junxia Wang (ORCID: https://orcid.org/0000-0002-2041-0416)
- Xinghua Li (ORCID: https://orcid.org/0000-0002-3275-2755)
- Xinyue Liu (ORCID: https://orcid.org/0000-0002-3479-4684)
- Yu Wang (ORCID: https://orcid.org/0009-0002-9822-440X)
- Yan Han (ORCID: https://orcid.org/0000-0002-6810-2957)
Institutions
- Shanxi Medical University (CN)
- Changzhi Medical College (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1675373
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00